NASDAQ · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · SMALL CAP
ImmuCell Corporation ICCC
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$27.6M
▲ 4.3% vs FY2024
EPS · FY25
$-0.12
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-3.8%
Net margin · FY25
-3.8%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 27.6M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
The company lost 4 cents on every revenue dollar this year.
Per share
USD -0.12
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-3.8%
Return on equity, FY2025
ROE
Operating margin6.0%
Net margin-3.8%
Return on assets-2.4%
Each USD of equity lost 4 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+12.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+14.2%
+12.5%
+10.5%
+13.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years+25.3%
Change, 10 years—
The share count grew 25% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 42.5M
total assets, end of FY2025
Total assetsUSD 42.5M
EquityUSD 27.1M
CashUSD 3.8M
Gross debtUSD 9.1M
Net debtUSD 5.3M
Current ratio4.26×
Net debt stands at 20% of equity.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
EBITDA $B
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
−0.0
0.0
0.0
−0.0
0.0
0.0
−0.0
−0.0
−0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
−0.0
0.0
0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.12
−0.26
−0.75
−0.32
−0.01
−0.14
−0.19
−0.42
−0.03
0.12
0.38
−0.06
0.04
0.03
−0.14
−0.13
−0.07
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−3.8
−8.2
−20.9
−7.9
−0.3
−3.6
−5.1
−10.2
−0.8
3.4
12.2
−1.8
1.3
1.0
−4.5
−4.1
−2.2
Shares out B
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.00
0.00
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
66 of 66
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed